受体酪氨酸激酶在胃癌中的作用：选择性治疗的新靶点。
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
作者信息
Becker J C, Muller-Tidow C, Serve H, Domschke W, Pohle T
出版信息
World J Gastroenterol. 2006 Jun 7;12(21):3297-305. doi: 10.3748/wjg.v12.i21.3297.
Abstract
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success.
摘要
受体酪氨酸激酶（RTK），如表皮生长因子受体家族，参与肿瘤形成的多个步骤，包括增殖和转移扩散。几种已知的RTK在胃癌中上调，是靶向治疗的主要靶点。然而，关于目前临床上可用的药物，如曲妥珠单抗、西妥昔单抗、贝伐单抗、吉非替尼、厄洛替尼和伊马替尼在胃癌治疗中的应用，仅有初步数据。临床前数据表明它们的使用可能有益，特别是与“传统”细胞抑制疗法联合使用时。本综述总结了目前关于它们在癌症治疗中的应用的知识，以及优化治疗效果的新方法和药物。
相似文献
1
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.受体酪氨酸激酶在胃癌中的作用：选择性治疗的新靶点。
World J Gastroenterol. 2006 Jun 7;12(21):3297-305. doi: 10.3748/wjg.v12.i21.3297.
2
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.从癌症治疗中的单靶点药物到多靶点药物：特异性何时成为一种优势。
Curr Med Chem. 2008;15(5):422-32. doi: 10.2174/092986708783503212.
3
[Antineoplastic agents targeting tyrosine kinases].[靶向酪氨酸激酶的抗肿瘤药物]
Tidsskr Nor Laegeforen. 2005 Nov 17;125(22):3115-9.
4
Recent advances of molecular targeted agents: opportunities for imaging.分子靶向药物的最新进展：成像机遇
Cancer Biol Ther. 2003 Nov-Dec;2(6):601-9.
5
[Resistance to target-based therapy and its circumvention].[对基于靶点治疗的耐药性及其规避]
Nihon Rinsho. 2004 Jul;62(7):1343-7.
6
Researchers optimistic about sea change in cancer treatment.研究人员对癌症治疗的重大变革持乐观态度。
JAMA. 2001 Jun 13;285(22):2841-2. doi: 10.1001/jama.285.22.2841.
7
[Problems in the current target therapy of malignancies].[恶性肿瘤当前靶向治疗中的问题]
Vopr Onkol. 2005;51(5):607-11.
8
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.靶向受体酪氨酸激酶erbB家族的抗癌疗法。
Semin Oncol. 2001 Oct;28(5 Suppl 16):67-79. doi: 10.1016/s0093-7754(01)90284-2.
9
[Molecular target therapy for malignant tumors].[恶性肿瘤的分子靶向治疗]
Nihon Naika Gakkai Zasshi. 2005 Feb 20;94 Suppl:76-80.
10
Beyond Herceptin and Gleevec.超越赫赛汀和格列卫。
Curr Opin Chem Biol. 2003 Aug;7(4):490-5. doi: 10.1016/s1367-5931(03)00082-6.
引用本文的文献
1
A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies.胃癌治疗最新进展的文献综述：探索靶向治疗之间的相互作用
Cancer Cell Int. 2025 Jan 24;25(1):23. doi: 10.1186/s12935-025-03655-8.
2
Repurposing of gastric cancer drugs against COVID-19.重新利用胃癌药物治疗 COVID-19。
Comput Biol Med. 2021 Oct;137:104826. doi: 10.1016/j.compbiomed.2021.104826. Epub 2021 Sep 6.
3
Tyrosine Kinases in Infections and Gastric Cancer.酪氨酸激酶在感染和胃癌中的作用。
Toxins (Basel). 2019 Oct 11;11(10):591. doi: 10.3390/toxins11100591.
4
Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival.基于新型分子生物标志物的胃癌免疫组织化学分类：一种潜在的生存预测指标。
Virchows Arch. 2018 Dec;473(6):687-695. doi: 10.1007/s00428-018-2443-9. Epub 2018 Aug 23.
5
Targeting receptor tyrosine kinases in gastric cancer.靶向胃癌中的受体酪氨酸激酶
World J Gastroenterol. 2014 Apr 28;20(16):4536-45. doi: 10.3748/wjg.v20.i16.4536.
6
Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.利用蛋白质芯片技术研究肝细胞癌中激活的受体酪氨酸激酶。
Exp Ther Med. 2011 May;2(3):399-403. doi: 10.3892/etm.2011.215. Epub 2011 Feb 8.
7
Resistance to TRAIL is mediated by DARPP-32 in gastric cancer.胃癌中 TRAIL 耐药性由 DARPP-32 介导。
Clin Cancer Res. 2012 Jul 15;18(14):3889-900. doi: 10.1158/1078-0432.CCR-11-3182. Epub 2012 May 15.
8
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.MET 激活介导了对曲妥珠单抗耐药的 HER2 扩增胃癌细胞对拉帕替尼的抑制作用。
Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.
9
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.表皮生长因子受体抑制剂增强伊立替康活性代谢物 SN38 在 SN38 耐药胃癌细胞中的疗效。
Br J Cancer. 2011 Nov 8;105(10):1522-32. doi: 10.1038/bjc.2011.397. Epub 2011 Oct 13.
10
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.DARPP-32 增加表皮生长因子受体和 ERBB3 之间的相互作用，促进肿瘤对吉非替尼的耐药性。
Gastroenterology. 2011 Nov;141(5):1738-48.e1-2. doi: 10.1053/j.gastro.2011.06.070. Epub 2011 Jul 7.
本文引用的文献
1
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.伊立替康、顺铂和贝伐单抗用于转移性胃或胃食管交界腺癌患者的多中心II期研究。
J Clin Oncol. 2006 Nov 20;24(33):5201-6. doi: 10.1200/JCO.2006.08.0887.
2
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.厄洛替尼用于胃食管交界腺癌和胃腺癌的II期试验：SWOG 0127
J Clin Oncol. 2006 Oct 20;24(30):4922-7. doi: 10.1200/JCO.2006.07.1316.
3
Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.靶向结直肠癌表皮生长因子受体通路的单克隆抗体和小分子概述
Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. doi: 10.3816/ccc.2005.s.010.
4
ERBB2 kinase domain mutation in a gastric cancer metastasis.胃癌转移中的ERBB2激酶结构域突变
APMIS. 2005 Oct;113(10):683-7. doi: 10.1111/j.1600-0463.2005.apm_284.x.
5
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.表皮生长因子受体（EGFR）、血管内皮生长因子受体（VEGFR）和血小板衍生生长因子受体信号通路的同时抑制与吉西他滨联合应用可治疗人胰腺癌，并延长原位裸鼠模型的生存期。
Cancer Res. 2005 Nov 15;65(22):10371-80. doi: 10.1158/0008-5472.CAN-05-1698.
6
Antibody-based therapies for colorectal cancer.用于结直肠癌的基于抗体的疗法。
Oncologist. 2005 Oct;10(9):701-9. doi: 10.1634/theoncologist.10-9-701.
7
Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.表达NK4的基因治疗与吉非替尼（ZD1839，易瑞沙）“量身定制”联合用于弥漫性腹膜硬化型胃癌的临床前研究。
Int J Cancer. 2006 Mar 15;118(6):1545-55. doi: 10.1002/ijc.21531.
8
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.吉非替尼和西妥昔单抗对携带表皮生长因子受体突变的非小细胞肺癌的不同作用。
J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238.
9
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.晚期胃肠道间质瘤患者在400mg伊马替尼治疗进展后改用每日800mg剂量的治疗结果。
Eur J Cancer. 2005 Aug;41(12):1751-7. doi: 10.1016/j.ejca.2005.04.034.
10
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.将拉帕替尼（GW572016）（一种ErbB1和ErbB2酪氨酸激酶的小分子抑制剂）与治疗性抗ErbB2抗体联合使用，可增强过表达ErbB2的乳腺癌细胞的凋亡。
Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
Zotero 插件